IL2 and myeloid sarcoma: Given that IL-2-mediated Treg expansion in vivo is in clinical trial for MS (clinical trial number NCT02424396)49, our findings are of translational importance as they suggest that Treg expansion as a potential pro-remyelination therapy may be limited in older populations.